Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suvodirsen Phase 2/3 in DMD (DYSTANCE 51)
NCT03907072Phase 3Terminated
- Sponsor
- Wave Life Sciences
- Start
- Sep 2019
- Primary completion
- Dec 2019
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of Suvodirsen in Duchenne muscular dystrophy (DMD) (3 arms), sponsored by Wave Life Sciences. Primary endpoints: Change From Baseline in Dystrophin Level (% Normal Dystrophin) at Week 46 and Change From Baseline in North Star Ambulatory Assessment at Week 48. Started Sep 2019; status: terminated.
02
Drugs
Suvodirsen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT03907072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03907072.